Trade NAMS stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
NewAmsterdam Pharma Company N.V. (NAMS) is trading at US$21.58, up 1.48% today as of Oct 9, 16:00 EDT. The company has a market capitalisation of US$3.33B. Over the past 52 weeks, NAMS has traded between US$20.91 and US$42.21. On Syfe you can trade NAMS with $0 commission and add it to your watchlist.
| Previous close | US$21.26 |
|---|---|
| Market cap | US$3.33B |
| 52-week range | US$20.91 – US$42.21 |
| Volume | 1.26M |
| Exchange | US |
NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.
Year: 2022
RBC Adjusts NewAmsterdam Pharma PT to $50 From $51, Maintains Outperform Speculative Risk Rating
Aug 6, 12:53 PM · MT Newswires
NewAmsterdam Pharma Company N.V. (NAMS) stock is trading at US$21.58, +1.48% from the previous close of US$21.26.
The market cap for NewAmsterdam Pharma Company N.V. (NAMS) stock is approximately US$3.33B.
The 52-week high for NewAmsterdam Pharma Company N.V. (NAMS) stock is US$42.21.
The 52-week low for NewAmsterdam Pharma Company N.V. (NAMS) stock is US$20.91.
NewAmsterdam Pharma Company N.V. (NAMS) does not currently pay a dividend.
Stay on top of NAMS
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
